K. Dear, R. Nixon
Introduction: Patch testing is the gold standard for accu- rately diagnosing allergic contact dermatitis (ACD). In
2002, the Australian Baseline series (ABS) was initiated based on the most frequent and signiﬁcant allergens in our population.
Patients at our tertiary referral centre are patch tested with the ABS, additional series and with their
own products. This study aimed to assess how well the ABS performed in detecting allergens alone.
Methods: Patients patch tested between 1st January 2012 and 31st December 2018 with a resulting diagnosis of ACD were identiﬁed. Case notes were reviewed and patients were classiﬁed as to whether the ABS identiﬁed all relevant allergens, only some relevant allergens, or none of the relevant allergens.
Results: All relevant allergens were identiﬁed from the ABS in nearly two thirds of cases (63%). In 23% of cases, allergens were identiﬁed from the ABS as well as from additional series or via patients’ own products. In a small number of cases (14%), allergens were only detected from additional series or by testing with patients’ own products. Overall, the ABS detected at least one relevant allergen in
86% of cases, however using the ABS alone has the poten- tial to miss a relevant reaction in 37% of cases.
Conclusion: Compared with the efﬁcacy of other baseline series, the ABS is a useful screening series to identify patients with ACD. However, patients should continue to be tested with additional series and their own products in order to ensure that all relevant allergens are identiﬁed.
1. Toholka R, Wang YS, Tate B, Tam M, Cahill J, Palmer A, Nixon R. The ﬁrst Australian Baseline Series: Recommendations for patch testing in suspected contact dermatitis. Australasian Jour- nal of Dermatology. 2015 May;56(2):107–15.
A non-interventional-prospective-12-month study to characterise REAL-life effectiveness and treatmentpatterns of secukinumab, and current standard-of-care of chronic plaque psoriasis in Asia-Pacific & MiddleEast